Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 7;8(1):e001221. doi: 10.1136/bmjdrc-2020-001221

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Histological analysis. (A) Representative high power field sections of the wound bed, Day 10. H&E, MT, anti-Ki-67, and anti-CD45-stained wounds treated with ATZ, MSA, and occlusive dressing (Chronic diabetic), wounds treated with ATZ, MSA, a collagen-glycosaminoglycan implant plus occlusive dressing (Treated chronic diabetic), and wounds covered with occlusive dressing (Diabetic control) on day 10. The scaffold was excluded from the histology and analysis. Scale bar=µ100 m. (B) Inflammatory tissue thickness, day 10. A significant difference in inflammatory tissue thickness was shown between the Diabetic control group and both ATZ+MSA treated groups. The ATZ+MSA treated groups did not differ between each other. (C) Collagen deposition, day 10. A significant difference in collagen deposition was shown between the Diabetic control group and both ATZ+MSA treated groups. The ATZ+MSA treated groups did not differ between each other. (D) Cellular proliferation, day 10. A significant difference in cellular proliferation was shown between the Diabetic control group and both ATZ+MSA treated groups. The ATZ+MSA treated groups did not differ between each other. (E) Leukocyte infiltration, day 10. A significant difference in leukocyte infiltration was shown between the Diabetic control group and both ATZ+MSA treated groups. The ATZ+MSA treated groups significantly differed. (F) H&E high-power examination of wound bed, day 10. Neutrophils and macrophages are the main cellular infiltrate components. The scaffold was excluded from the histological analysis. Scale bar=µ50 m. *p<0.05, **p<0.01, ***p<0.001. ATZ, 3-amino-1,2,4-triazole; MSA, mercaptosuccinic acid; MT, Masson’s trichrome.